Internal Medicine, Medical Oncology · Hackensack, NJ
NPI
1306805460
Since 2006
Specialty
Internal Medicine, Medical Oncology
Code 207RX0202X
Group practices
2
Medicare group memberships
Hospitals
5
Hospital affiliations
92 2nd St
Hackensack, NJ, 07601
Phone (551) 996-5072
Groups this clinician bills Medicare through
Medicare paid, 2024
$888K
43,309 services
Medicare patients, 2024
800
Average age 75
Drug cost, 2024
$9.4M
2,174 prescriptions
Company payments, 2025
$40K
From 31 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Robert S Alter was code J0885 (injection, epoetin alfa, (for non-esrd use), 1000 units), 7,540 times for 39 patients. In total Robert S Alter billed 43,309 services in 58 codes, and Medicare paid $888K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2022-01-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 7,540 | 39 | $6.28 | $47K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,829 | 627 | $13.78 | $25K |
| 99214 Office E&M - Established | Office | 1,193 | 541 | $104.00 | $124K |
| 99215 Office E&M - Established | Office | 1,031 | 265 | $149.22 | $154K |
| Q5111 Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 864 | 27 | $106.74 | $92K |
| Q5106 Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units | Office | 560 | 11 | $5.99 | $3,354 |
| 96372 Injection Administration | Office | 332 | 66 | $12.26 | $4,072 |
| 99232 Hospital E&M - Subsequent | Facility | 212 | 91 | $66.31 | $14K |
| 85025 Blood Count | Office | 172 | 86 | $7.61 | $1,309 |
| 99205 Office E&M - New | Office | 106 | 106 | $182.46 | $19K |
| 99223 Hospital E&M - Initial | Facility | 65 | 61 | $143.92 | $9,355 |
| 99239 Hospital Discharge Management | Facility | 29 | 27 | $97.33 | $2,823 |
| 85027 Blood Count | Office | 26 | 15 | $6.34 | $165 |
| G2212 Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 15 | 11 | $27.74 | $416 |
By year: 2022 $960K for 33,897 services; 2023 $948K for 31,111 services; 2024 $888K for 43,309 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 85025 Blood Count | 172 | 86 | $7.61 | $1,309 |
| 85027 Blood Count | 26 | 15 | $6.34 | $165 |
Medicare prescription drug claims, 2024
In 2024, the drug Robert S Alter prescribed most often to Medicare patients was Abiraterone Acetate, with 454 prescriptions and refills. In total Robert S Alter wrote 2,174 Medicare prescriptions that cost $9.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Abiraterone Acetate Generic | 454 | 530 | 71 | $560K |
| Prednisone Generic | 371 | 464 | 91 | $1,589 |
| Ondansetron Hcl Generic | 110 | 110 | 59 | $587 |
| Xtandi Enzalutamide | 104 | 104 | 19 | $1.2M |
| Prochlorperazine Maleate Generic | 104 | 104 | 61 | $1,140 |
| Nubeqa Darolutamide | 92 | 92 | 12 | $1.2M |
| Cabometyx Cabozantinib S-Malate | 91 | 91 | 17 | $1.6M |
| Levothyroxine Sodium Generic | 78 | 150 | 19 | $538 |
| Orgovyx Relugolix | 59 | 64 | 19 | $147K |
| Erleada Apalutamide | 51 | 51 | Under 11 | $555K |
| Lenvima Lenvatinib Mesylate | 49 | 49 | Under 11 | $1.2M |
| Raloxifene Hcl Generic | 47 | 119 | 12 | $2,188 |
| Inlyta Axitinib | 39 | 39 | Under 11 | $675K |
| Eliquis Apixaban | 38 | 40 | Under 11 | $23K |
| Bicalutamide Generic | 32 | 62 | Under 11 | $620 |
Brand drugs: 709 claims; generic drugs: 1,465 claims; opioid claims: 36.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Robert S Alter $40K ($40K in general payments such as food, travel and fees) from 31 companies. The largest payer was Astellas Pharma US Inc with $14K.
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc 4503.T | 13 | $14K |
| Janssen Biotech, Inc. JNJ | 16 | $9,018 |
| Eisai Inc. 4523.T | 25 | $7,532 |
| AstraZeneca Pharmaceuticals LP AZN | 12 | $2,920 |
| Exelixis Inc. EXEL | 4 | $2,812 |
| Novartis Pharmaceuticals Corporation NVS | 11 | $2,258 |
| Pfizer Inc. PFE | 13 | $248 |
| Merck Sharp & Dohme LLC MRK | 11 | $247 |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 9 | $189 |
| Fennec Pharmaceuticals, Inc. FENC | 4 | $184 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.